JAAD international · 2025
Efficacy and safety of twice- or thrice-weekly dutasteride versus daily finasteride in men with androgenetic alopecia: A randomized, investigator-blinded, active-controlled, parallel-group pilot study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sereepanpanich Varalee, Khunkhet Saranya, Rojhirunsakool Salinee, Udompataikul Montree
Аннотация
BACKGROUND: Dutasteride is sometimes used in treating male androgenetic alopecia; however, published data on intermittent regimens are scant.
OBJECTIVE: To evaluate efficacy and safety of twice-weekly and thrice-weekly regimens of dutasteride, and to compare with finasteride, in men with androgenetic alopecia.
METHODS: Sixty men, aged 21 to 60 years, were randomized to receive dutasteride 0.5 mg twice weekly, dutasteride 0.5 mg thrice weekly, or finasteride 1 mg daily for 24 weeks. Efficacy was evaluated by changes of hair density and diameter using videodermoscopy, and global photographic assessment.
RESULTS: Hair density and diameter significantly increased after treatment in 3 groups (all P < .05), showing a dose-dependent manner among dutasteride groups. Mean changes of terminal hair count from baseline in twice-weekly dutasteride, thrice-weekly dutasteride, and once-daily finasteride were 7.74, 17.43, and 12.81 hairs/cm2, respectively. Thrice-weekly dutasteride showed a greater moderate-to-marked improvement than once-daily finasteride (35% vs 21%). Sexual adverse events were similar among 3 groups.
LIMITATIONS: Unblinded participants to treatment allocation.
CONCLUSION: Twice-weekly and thrice-weekly regimens of dutasteride increased hair growth and were well-tolerated. Although thrice-weekly dutasteride was significantly superior to twice-weekly dutasteride, in terms of hair density and diameter, thrice-weekly dutasteride did not significantly increase hair count over finasteride 1 mg daily.
OBJECTIVE: To evaluate efficacy and safety of twice-weekly and thrice-weekly regimens of dutasteride, and to compare with finasteride, in men with androgenetic alopecia.
METHODS: Sixty men, aged 21 to 60 years, were randomized to receive dutasteride 0.5 mg twice weekly, dutasteride 0.5 mg thrice weekly, or finasteride 1 mg daily for 24 weeks. Efficacy was evaluated by changes of hair density and diameter using videodermoscopy, and global photographic assessment.
RESULTS: Hair density and diameter significantly increased after treatment in 3 groups (all P < .05), showing a dose-dependent manner among dutasteride groups. Mean changes of terminal hair count from baseline in twice-weekly dutasteride, thrice-weekly dutasteride, and once-daily finasteride were 7.74, 17.43, and 12.81 hairs/cm2, respectively. Thrice-weekly dutasteride showed a greater moderate-to-marked improvement than once-daily finasteride (35% vs 21%). Sexual adverse events were similar among 3 groups.
LIMITATIONS: Unblinded participants to treatment allocation.
CONCLUSION: Twice-weekly and thrice-weekly regimens of dutasteride increased hair growth and were well-tolerated. Although thrice-weekly dutasteride was significantly superior to twice-weekly dutasteride, in terms of hair density and diameter, thrice-weekly dutasteride did not significantly increase hair count over finasteride 1 mg daily.